| Adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes-a systematic review. | 2024 | Pharmacology Research & Perspectives |
| Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: A network meta-analysis. | 2024 | Frontiers in Endocrinology |
| Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials. | 2023 | Diabetes, Obesity & Metabolism |
| Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: A meta-analysis of randomized controlled trials. | 2023 | Cardiovascular Diabetology |
| Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. | 2023 | Frontiers in Pharmacology |
| The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: A systematic review of randomized controlled trials. | 2023 | Medicina |
| Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: Systematic review and network meta-analysis. | 2023 | Acta Diabetologica |
| The efficacy of sodium-glucose cotransporter-2 inhibitors in improving morbidity and mortality of heart failure: A systematic review. | 2023 | Cureus |
| Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: A meta-analysis of cohort studies. | 2023 | Frontiers in Pharmacology |
| Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis. | 2023 | Frontiers in Pharmacology |
| Comparative efficacy and safety of sodium-glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. | 2023 | Renal Failure |
| Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. | 2023 | Frontiers in Endocrinology |
| Clinical efficacy of different doses of canagliflozin combined with metformin in the treatment of type 2 diabetes: Meta-analysis. | 2023 | Alternative Therapies in Health and Medicine |
| Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials. | 2023 | Diabetes, Obesity & Metabolism |
| Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: A systematic review and network meta-analysis of randomized controlled trials. | 2023 | Frontiers in Endocrinology |
| Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of randomized clinical trials. | 2023 | Frontiers in Endocrinology |
| Impact of SGLT2 inhibitors on patient outcomes: A network meta-analysis. | 2023 | Cardiovascular Diabetology |
| The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: A systematic review and meta-analysis of randomized controlled trials. | 2023 | BMC Endocrine Disorders |
| Treatments for chronic kidney disease: A systematic literature review of randomized controlled trials. | 2022 | Advances in Therapy |
| Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: A systemic review and meta-analysis of randomized controlled trials. | 2022 | Journal of Cardiovascular Pharmacology |
| Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. | 2022 | Frontiers in Endocrinology |
| Comparative efficacy of five SGLT2i on cardiorenal events: a network meta-analysis based on ten CVOTs. | 2022 | American Journal of Cardiovascular Drugs |
| Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: A systematic review and meta-analysis. | 2022 | Journal of Diabetes Research |
| Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: A systematic review and meta-analysis. | 2022 | Canadian Journal of Diabetes |
| Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis. | 2022 | Journal of Family Medicine and Primary Care |
| Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: A network meta-analysis and systematic review. | 2022 | International Urology and Nephrology |
| Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. | 2022 | Diabetes, Obesity & Metabolism |
| Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. | 2022 | Frontiers in Pharmacology |
| SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. | 2022 | European Journal of Pharmacology |
| Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. | 2022 | Frontiers in Endocrinology |
| Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis. | 2022 | Archives of Endocrinology and Metabolism |
| Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: A systematic review and head-to-head comparative efficacy network meta-analysis. | 2022 | Clinical Research in Cardiology |
| Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: A meta-analysis. | 2022 | Journal of Hypertension |
| Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors and combined SGLT1/2 inhibitors on cardiovascular, metabolic, renal, and safety outcomes in patients with diabetes: A network meta-analysis of 111 randomized controlled trials. | 2022 | American Journal of Cardiovascular Drugs |
| Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. | 2022 | Diabetes & Metabolic Syndrome |
| Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial. | 2022 | Diabetes, Obesity & Metabolism |
| Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. | 2022 | Diabetes, Obesity & Metabolism |
| Microvascular benefits of new antidiabetic agents: a systematic review and network meta-analysis of kidney outcomes. | 2021 | The Journal of Endocrinology & Metabolism |
| Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. | 2021 | Medicine |
| Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. | 2021 | Heart Rhythm |
| Comparative efficacy of dual and single initiation of add-on oral antihyperglycemic agents in type 2 diabetes uncontrolled on metformin alone: a systematic literature review and network meta-analysis. | 2021 | Diabetes Therapy |
| Effect of SGLT-2 inhibitors on non-alcoholic fatty liver disease among patients with type 2 diabetes mellitus: systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. | 2021 | Oman Medical Journal |
| Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and meta- analysis of randomized placebo-controlled trials. | 2021 | Frontiers in Endocrinology |
| Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and cardiovascular outcomes in adults with type 2 diabetes: a Bayesian meta-analysis and meta-regression. | 2021 | Journal of the American Heart Association |
| High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: a meta-analysis of randomized clinical trials. | 2021 | Diabetes, Obesity and Metabolism |
| Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. | 2021 | Heart Failure Reviews |
| Comparative efficacy of glucose-lowering medications on bodyweight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. | 2021 | Diabetes, Obesity and Metabolism |
| Safety and efficacy of SGLT2 inhibitors: a multiple-treatment meta-analysis of clinical decision indicators. | 2021 | Journal of Clinical Medicine |
| Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials. | 2021 | Primary Care Diabetes |
| Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases. | 2021 | Medicine |
| Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: A systematic review of population-based observational studies. | 2021 | Diabetes Therapy |
| Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. | 2021 | Diabetes & Vascular Disease Research |
| Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis. | 2021 | Medicine |
| Canagliflozin for prevention of cardiovascular and renal outcomes in type2 diabetes: A systematic review and meta-analysis of randomized controlled trials. | 2021 | Frontiers in Pharmacology |
| Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis. | 2021 | Diabetes, Obesity & Metabolism |
| SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. | 2021 | Cardiovascular Diabetology |
| Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials. | 2021 | European Journal of Clinical Pharmacology |
| Comparative efficacy of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events in type 2 diabetes: A network meta-analysis. | 2021 | Journal of Cardiovascular Pharmacology |
| Meta-analysis of dedicated renal outcome trials assessing the cardio-renal efficacy of sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease and albuminuria. | 2021 | American Journal of Cardiology |
| Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis. | 2020 | Annals of Internal Medicine |
| Cardiovascular outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and chronic kidney disease: An updated meta-analysis of randomized controlled trials. | 2020 | Cardiology in Review |
| Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: A systematic review and meta-analysis. | 2020 | Medical Sciences |
| Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials. | 2020 | Diabetes Research and Clinical Practice |
| Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials. | 2020 | Journal of Endocrinology and Metabolism |
| The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: A systematic review and meta-analysis. | 2020 | Cardiorenal Medicine |
| Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: A systematic literature review and network meta-analysis. | 2019 | Diabetes Therapy |
| Peripheral artery disease and amputations with sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials . | 2019 | Diabetes Research and Clinical Practice |
| SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. | 2019 | The Lancet Diabetes & Endocrinology |
| Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. | 2019 | Medicine |
| Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. | 2019 | PLoS Medicine |
